As we prepare to enter the next decade of this revolutionary law, we cordially invite you to join us for ACI’s 13th Annual Biosimilars & Innovator Biologics Summit.
As the number of FDA-approved biosimilar products continues to grow, the need for a solid guiding framework becomes more critical than ever before. While the stakeholders wait for finality on the rules governing significant matters like interchangeability, substitution and equivalency, it is clear that biosimilars will remain a top priority for the FDA.
The biosimilars market continues to maintain momentum as we head into 2021, but questions remain as to whether the U.S. market will catch up with Europe and whether biosimilars will provide their intended cost-savings.
Join the “who’s who” of the biosimilars and innovator biologics industries as they gather for ACI’s 2021 Summit on Biosimilars & Innovator Biologics and contemplate these and other probing questions.
Who You Will Meet
In-house counsel from branded and biosimilars companies
from the FDA, USPTO, and the Judiciary
Leading regulatory and patent attorneys from around the country
About this Conference
Prepare to enter the next decade of this revolutionary law.
Biologics have become the fastest-growing class of therapeutic compounds. They have provided innovative treatment alternatives for people who suffer from some of the most serious medical conditions known to man. The incorporation of biosimilar products into the U.S. marketplace was designed to improve patient access and decrease healthcare costs. While much has evolved since the enactment of the BPCIA, the traditional barriers remain.
Now, more than ever, strategies to overcome these barriers are essential to improve the understanding of biosimilar products in the United States. The need for a solid guiding framework becomes more critical than ever before.
The next decade will see more litigation in this sphere. Further, and to an increasing extent, IPR proceedings challenging patents protecting biologic medicines, including IPRs filed before any action was taken under the BPCIA. Finally, the future will usher in considerable changes growing the scope of products that are regulated and litigated under the BPCIA.
Join the “who’s who” of the biosimilars and innovator biologics industries as they gather virtually to discuss and contemplate the impact of these critical developments.
2021 Conference Recording
Missed last year’s conference? Watch a recording of the 12th annual event.PURCHASE RECORDING
In-House Town Hall: An Insider’s Guide to What In-House Counsel Expect from Law Firm Counterparts.Watch Now
Year after year, the ACI Biosimilar Conference has featured a top-notch faculty from the pharma/biotech industry, private practice and government to address hot-button issues in this rapidly evolving area — I am looking forward to another outstanding event.
Immac “Casey” Thampoe
Executive Director/Assistant General Counsel
IP Portfolio Development
Regeneron Pharmaceuticals, Inc.
If I had to pick only one event to get the latest on issues impacting biosimilars, it would be the ACI Biosimilar Conference — highly informative presentations and ample opportunities to network and catch-up with players in this space.
Charles K. Sholtz
Director and Associate General Counsel
Biosimilars, Manufacturing & Litigation Readiness Lead
ACI’s Global Series of Life Sciences Conferences bring together key sector stakeholders from around the globe to explore the most important trends impacting the many industries including pharmaceutical, biotechnology, medical device/diagnostics, and FDA-regulated consumer products. Our events cover every facet of legal and business relevance as well as controversy. Learn More